Secukinumab: A Review in Moderate to Severe Plaque Psoriasis

Garnock-Jones, Karly P.

doi:10.1007/s40257-015-0143-7

Cited by 40 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tildrakizumab is a humanized IgG1/𝜅 MAB, which has high affinity for IL-23p19, but no affinity for IL-12 or IL-23p40 [40]. Secukinumab is a first-in-class IgG1𝜅, fully human MAB targeting IL-17A [41]. Ixekizumab is a humanized IgG4 MAB that neutralizes IL-17A [42].…”

Section: Resultsmentioning

confidence: 99%

Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger?

2018

View full text Add to dashboard Cite

Background: Psoriasis is a common, chronic inflammatory skin disorder, which can significantly impact quality of life. Despite major breakthroughs in our understanding of the pathogenesis of psoriasis, the chronological order of the underlying mechanisms leading to the development of psoriatic plaques remains to be completely understood. Summary: Although psoriasis is classically perceived as a T-cell disease, it is now well recognized that T lymphocytes do not function in exclusivity. This theory is supported by evidence from transgenic murine models that develop marked psoriasiform disease. In addition, immune cells and cytokines regulate both early and late events involved in the pathogenesis of psoriasis. Key Messages: Psoriasis is a complex disease – a dynamic interplay between immune cells, keratinocytes, and various other skin-resident cells, such as endothelial and immune cells. The contribution of each cell type is crucial in the initiation and maintenance phases of psoriatic alterations.

show abstract

Section: Resultsmentioning

confidence: 99%

Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger?

2018

View full text Add to dashboard Cite

show abstract

“…In recent years several therapies directed against Th17-related cytokines, including IL-17, IL-23, and GM-CSF, have been developed, and some are currently being tested in ongoing clinical trials ( Table 1 ). The fully humanized antibody neutralizing IL-17A called AIN457 or Secukinumab ( NCT01708603 Clinicaltrial.gov) is already approved for the first-line systemic treatment of moderate to severe plaque psoriasis [ 154 , 155 ]; in MS patients, although it showed a reduction by 63% of new magnetic resonance imaging (MRI) lesions compared to placebo-treated patients, the reduction of annualized relapse rate (ARR) was not statistically significant [ 71 ]. Moreover, Secukinumab was ineffective and resulted in higher rates of adverse events, mainly infections, compared with placebo in patients with Crohn's disease [ 156 ], and the study in MS terminated early based upon development of another anti-IL-17 monoclonal antibody with better potential for treating MS patients, Ixekizumab ( NCT02387801 Clinicaltrial.gov).…”

Section: Therapeutic Approaches Targeting Th17 Cells In Msmentioning

confidence: 99%

Advances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis

Volpe

Battistini

Borsellino

2015

Mediators of Inflammation

View full text Add to dashboard Cite

The discovery of the T helper (Th) 17 lineage, involved in the protection against fungal and extracellular bacterial infections, has profoundly revolutionized our current understanding of T cell-mediated responses in autoimmune diseases, including multiple sclerosis (MS). Indeed, recent data demonstrate the pathogenic role of Th17 cells in autoimmune disorders. In particular, studies in MS and in its animal model (EAE, experimental autoimmune encephalomyelitis) have revealed a crucial role of Th17 cells in the pathogenesis of autoimmune demyelinating diseases in both mice and humans. Over the past years, several important aspects concerning Th17 cells have been elucidated, such as the factors which promote or inhibit their differentiation and the effector cytokines which mediate their responses. The identification of the features endowing Th17 cells with high pathogenicity in MS is of particular interest, and discoveries in Th17 cell biology and function could lead to the design of new strategies aimed at modulating the immune response in MS. Here, we will discuss recent advances in this field, with particular focus on the mechanisms conferring pathogenicity in MS and their potential modulation.

show abstract

“…This review focuses on the clinical use of secukinumab in adults with active AS [9, 10]. Secukinumab is also approved for the treatment of plaque psoriasis [11] and psoriatic arthritis [12]; discussion of these indications is beyond the scope of this review.…”

Section: Introductionmentioning

confidence: 99%

Secukinumab: A Review in Ankylosing Spondylitis

Blair

2019

Drugs

View full text Add to dashboard Cite

Secukinumab (Cosentyx®), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and symptoms of AS versus placebo in three of four phase III trials. The benefits of secukinumab were generally seen regardless of whether patients had or had not received previous tumour necrosis factor (TNF) inhibitor therapy, and were sustained during longer-term (up to 5 years) treatment. Secukinumab was also associated with improvements in spinal mobility, physical function, health-related quality of life and work productivity in some of the trials. In MEASURE 1, secukinumab reduced inflammation in the sacroiliac joint, and slowed radiographic progression. Secukinumab was generally well tolerated during up to 5 years’ treatment; the most commonly reported adverse event was nasopharyngitis. In the minority of patients who developed anti-drug antibodies (ADAs), ADAs did not decrease efficacy or increase adverse events. In conclusion, secukinumab is an effective therapy for TNF inhibitor-naive patients with active AS, and provides a useful treatment option for patients who have an inadequate response to or are intolerant of TNF inhibitors.

show abstract

Secukinumab: A Review in Moderate to Severe Plaque Psoriasis

Cited by 40 publications

References 22 publications

Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger?

Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger?

Advances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis

Secukinumab: A Review in Ankylosing Spondylitis

Contact Info

Product

Resources

About